Niagen Bioscience indicators unique licence deal for PD remedy

The corporate holds the proper to hunt regulatory approval for a pharmaceutical NR remedy for PD sufferers. Credit score: R Images Background/Shutterstock.

Niagen Bioscience has secured a worldwide unique industrial licence settlement with Haukeland College Hospital, Bergen, Norway, for the event of a remedy for Parkinson’s illness (PD).

The settlement grants Niagen Bioscience unique rights to proprietary mental property, know-how and knowledge, important for future regulatory filings within the European Union underneath European Medicines Company pointers for the potential remedy of PD utilizing its patented nicotinamide riboside (Niagen) molecule.

It’s now the one firm that holds the proper to hunt regulatory approval for a pharmaceutical nicotinamide riboside (NR) remedy for PD sufferers.

Niagen Bioscience can select to commercialise the drug candidate independently or sublicense the programme to a strategic pharmaceutical accomplice.

Niagen Bioscience CEO Rob Fried said: “This milestone underscores our long-term dedication to translating scientific innovation into significant therapeutic options.”

A key aspect of this settlement is entry to scientific knowledge from the NOPARK trial, the most important scientific investigation of NAD+ augmentation in early PD thus far.

Accomplished in June 2025, the research concerned 400 people with early-stage PD throughout 12 websites in Norway, who acquired both 500mg of nicotinamide riboside or placebo for 52 weeks. The first endpoint was the MDS-UPDRS complete rating, a normal measure of PD development.

Professor Charalampos Tzoulis, who leads the NOPARK research, commented, “This is a crucial milestone in our efforts to convey a probably disease-modifying remedy for PD nearer to sufferers.” He highlighted the settlement as a big step in the direction of creating therapies for PD and different neurodegenerative problems.

The settlement builds on a collaboration between Haukeland College Hospital’s Dr Charalampos Tzoulis and Niagen Bioscience’s exterior analysis programme, CERP. Since March 2018, CERP has supported 300 analysis collaborations and greater than 35 peer-reviewed scientific research, together with a number of assessing the therapeutic potential of Niagen NR for PD.

Along side the licence settlement, Niagen Bioscience has established a wholly-owned subsidiary, marking a pivotal step in its transition from complement science to regulated drug growth for neurodegenerative ailments with excessive unmet wants.

Pharmaceutical Know-how Excellence Awards – Have you ever nominated?

Nominations at the moment are open for the distinguished Pharmaceutical Know-how Excellence Awards – one of many business’s most recognised programmes celebrating innovation, management, and affect. That is your likelihood to showcase your achievements, spotlight business developments, and acquire world recognition. Do not miss the chance to be honoured among the many greatest – submit your nomination as we speak!

Nominate Now